DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

  • Stage II-IV disease

• The following histologic epithelial cell types are eligible:

  • Serous adenocarcinoma
  • Mucinous adenocarcinoma
  • Clear cell adenocarcinoma
  • Transitional cell carcinoma
  • Adenocarcinoma not otherwise specified
  • Endometrioid adenocarcinoma
  • Undifferentiated carcinoma
  • Mixed epithelial carcinoma
  • Malignant Brenner's tumor
• Optimal (≤ 1 cm residual disease) OR suboptimal residual disease after initial debulking surgery (performed within the past 12 weeks)

• Synchronous primary endometrial cancer OR prior history of endometrial cancer allowed provided all of the following are true:

  • Stage IB disease or less
  • Less than 3 mm invasion without vascular or lymphatic invasion

  • No poorly differentiated subtypes, including the following:

    • Papillary serous
    • Clear cell
    • Other FIGO grade 3 lesions
• No epithelial tumors of low malignant potential (borderline tumors)
• No CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, or brain metastases by history or evidence upon physical examination within the past 6 months

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• GOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• INR ≤ 1.5
• PTT < 1.2 times upper limit of normal (ULN)
• No active bleeding or pathologic conditions carrying high risk of bleeding (e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels)

Hepatic

• AST ≤ 3 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 3 times ULN
• Bilirubin ≤ 1.5 times ULN
• No acute hepatitis

Renal

• Creatinine ≤ 2.0 mg/dL
• Urine protein-creatinine ratio < 1.0 OR protein 1.0 g by 24 hour urine collection

Cardiovascular

• Cardiac conduction abnormalities (e.g., bundle branch block or heart block) allowed provided the patient's cardiac status has been stable for ≥ 6 months before study entry

• No clinically significant cardiovascular disease, including any of the following:

  • Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg
  • Myocardial infarction or unstable angina within the past 6 months
  • New York Heart Association class II-IV congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Peripheral vascular disease ≥ CTCAE grade 2 (at least brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit)
  • No history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within the past 6 months

Other

• Not pregnant or nursing
• Fertile patients must use effective contraception during and for ≥ 6 months after completion of bevacizumab therapy
• No neuropathy (sensory and motor) > grade 1
• No active infection requiring antibiotics
• No circumstances that would preclude study participation
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• No history of allergic reaction to polysorbate 80 (e.g., etoposide, vitamin E)
• No other invasive malignancies within the past 5 years except non-melanoma skin cancer or localized breast cancer
• No serious, non-healing wound, ulcer, or bone fracture
• No significant traumatic injury within 28 days prior to bevacizumab therapy

• No prior history of abdominal fistula or gastrointestinal perforation within the past 3-6 months

  • Granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection allowed but require weekly wound examinations
• No clinical symptoms or signs of gastrointestinal obstruction requiring parenteral hydration and/or nutrition
• At least 28 days since intra-abdominal abscess and recovered

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• At least 3 years since prior adjuvant chemotherapy for localized breast cancer

  • Patients must remain free of recurrent or metastatic disease

Endocrine therapy

• Not specified

Radiotherapy

• At least 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin

  • Patient must remain free of recurrent or metastatic disease
• No prior radiotherapy to any portion of the abdominal cavity or pelvis

Surgery

• See Disease Characteristics
• No concurrent major surgical procedure or open biopsy or within 28 days prior to bevacizumab therapy
• No core biopsy within 7 days prior to bevacizumab therapy

Other

• No prior therapy for this malignancy
• No prior cancer treatment that contraindicates study therapy
• No prior anti-VEGF drug, including bevacizumab
• No concurrent amifostine or other protective agents